Physician profile
Min Pan
NPI 1184678393
$11,431.61
in general payments reported to CMS, 2019-2025
54 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,051 · 2020: $3,655 · 2021: $1,312 · 2022: $744 · 2023: $1,182 · 2024: $773 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,652.18 | 2019-2025 | |
| Abbvie INC. | $1,176.55 | 2020-2025 | |
| Emd Serono, INC. | $979.88 | 2019-2022 | |
| Allergan, INC. | $912.86 | 2019-2022 | |
| Pfizer INC. | $815.39 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $730.65 | 2019-2021 | |
| Biogen, INC. | $609.83 | 2019-2024 | Vumerity, Tysabri |
| Sunovion Pharmaceuticals INC. | $599.65 | 2019-2022 | |
| Ucb, INC. | $455.59 | 2019-2021 | |
| Genentech USA, INC. | $368.87 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $297.91 | 2019-2020 | |
| Genzyme Corporation | $292.68 | 2019-2022 | |
| Amgen INC. | $239.84 | 2019-2021 | |
| Greenwich Biosciences, INC. | $212.71 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $167.30 | 2020-2024 | Acthar |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.